Search clinical trials for: Checkpoint Inhibition

Total 6001 results

Institut Bergonié

Active, not recruiting

Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients (OPTIMUNELUNG)

Non Small Cell Lung Cancer

France
University Hospital, Ghent
Jules Bordet Institute; AZ Sint-Lucas Gent; GZA Ziekenhuizen Campus Sint-Augustinus and other collaborators

Completed

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors (CHEERS)

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma

Belgium
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION)

Gastroesophageal Cancer | Immune Checkpoint Inhibition

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Bayer

Active, not recruiting

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Colon Cancer | Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer

United States
NYU Langone Health
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Muscle-invasive Urothelial Cancer of the Bladder

United States
National Cancer Institute (NCI)

Completed

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer | Colorectal Neoplasms | Colorectal Tumors | Colorectal Carcinoma | Colorectal Cancer With Hepatic Metastases

United States
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Refractory Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Vanderbilt University; Avon Breast Health Access Fund

Active, not recruiting

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) (PRISMM)

Metastatic Solid Tumor | SF3B1 Gene Mutation | Spliceosome Mutation | U2AF1 Gene Mutation | SRSF2 Gene Mutation

United States
Herlev Hospital
Bristol-Myers Squibb

Completed

Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (CheckPAC)

Metastatic Pancreatic Cancer | Metastatic Biliary Tract Cancer

Denmark
National Institute of Neurological Disorders and...

Completed

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

Glioblastoma

United States
Children's National Research Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Melanoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

United States
National Cancer Institute (NCI)

Completed

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Hepatocellular Cancer | Metastatic Pancreatic Cancer | Liver Metastasis

United States
University of Wisconsin, Madison
AstraZeneca

Terminated

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV

United States
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma

United States, Argentina, Brazil, Australia, Singapore, New Zealand, Russian Federation, Mexico, Peru, Chile
National Cancer Institute (NCI)

Completed

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Hepatocellular Carcinoma | Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer

United States
Duke University

Withdrawn

SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer (STICk-IM-NSCLC)

Non Small Cell Lung Cancer | Brain Metastases

United States
Haider Mahdi
Mirati Therapeutics Inc.

Withdrawn

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Solid Tumors | Recurrent Endometrial Cancer

United States
University of Erlangen-Nürnberg Medical School

Completed

Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition (ST-ICI)

Metastatic Cancer

Germany
Novartis Pharmaceuticals

Completed

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Triple-negative Breast Cancer

Belgium, Italy, Japan, Taiwan, United States, Australia, Singapore, Spain, Germany, Korea, Republic of, Argentina, Canada, France, Hungary, Israel, Lebanon, Thailand
University of Southampton
Bristol-Myers Squibb

Active, not recruiting

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM)

Mesothelioma

United Kingdom
University of Cologne
Ludwig-Maximilians - University of Munich; Universitätsklinikum Hamburg-Eppendorf

Completed

ImPACt on Invasive Fungal Infections by Immune Checkpoint Inhibition (PACIFIC)

Invasive Fungal Infections

Germany
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma

United States
Bayer

Completed

Study of BAY1834942 in Patients With Solid Tumors

Advanced CEACAM6-expressing Solid Tumors

United States, Singapore, Canada
Australasian Gastro-Intestinal Trials Group

Completed

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer (MODULATE)

Colorectal Cancer Metastatic

Australia
National Cancer Institute (NCI)

Completed

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas

United States
Andrew J. Armstrong, MD

Completed

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC)

Prostate Cancer

United States
The Clatterbridge Cancer Centre NHS Foundation...
Bristol-Myers Squibb; University of Liverpool

Active, not recruiting

CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer (NICO)

Squamous Cell Carcinoma of the Oral Cavity

United Kingdom
Qianfoshan Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Immune Checkpoint Inhibition

China
TME Pharma AG
Merck Sharp & Dohme LLC

Completed

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (Keynote-559)

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer

Germany
Massachusetts General Hospital

Completed

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Melanoma | Glioblastoma | Intracranial Tumors

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Mundipharma-EDO GmbH

Withdrawn

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

United Kingdom
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Withdrawn

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
NYU Langone Health
AstraZeneca

Withdrawn

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Singapore General Hospital
National University Hospital, Singapore; National Cancer Center Singapore,... and other collaborators

Withdrawn

Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL (DuRIANS)

EBV Related Non-Hodgkin's Lymphoma | Primary CNS Lymphoma | Primary Testicular Lymphoma

Singapore
University of Kansas Medical Center

Withdrawn

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Carcinoma, Renal Cell

United States
NHS Greater Glasgow and Clyde
University of Glasgow

Unknown

Inhibition of Co-Stimulation in Rheumatoid Arthritis (ICoSRA)

Arthritis, Rheumatoid

United Kingdom
Astellas Pharma Inc

Completed

A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia

Functional Dyspepsia | Dyspepsia

Japan
Orrin M Troum, M.D. and Medical Associates
Bristol-Myers Squibb

Completed

Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

Rheumatoid Arthritis

United States
Washington University School of Medicine
Bristol-Myers Squibb

Completed

The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics (CIA)

Atopic Asthma

United States
Xijing Hospital

Recruiting

Preoperative Adjuvant SOX Plus PL-1 Antibody and FLOT Plus PD-1 Antibody for Locally Advanced dMMR Gastric Cancer

Gastric Cancer | Chemotherapeutic Toxicity | Immune-related Adverse Event

China
Escola Superior de Tecnologia da Saúde do Porto

Not yet recruiting

Effectiveness of the Suboccipital Inhibition Technique in Forward Head Posture.

Individuals With Forward Head Posture

Portugal
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma
M.D. Anderson Cancer Center
Incyte Corporation

Not yet recruiting

Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Advanced Cholangiocarcinoma | FGFR2 Fusion

United States
Mayo Clinic

Recruiting

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Malignant Solid Neoplasm | Melanoma | Renal Cell Carcinoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Lung Small Cell Carcinoma

United States
Riphah International University

Recruiting

Comparison of INIT and Dry Needling on Trigger Points in Knee OA

Knee Osteoarthritis

Pakistan
Sun Yat-sen University

Recruiting

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Malignant Ascites

China
Amgen

Not yet recruiting

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (Eucalyptus)

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Sichuan University

Recruiting

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

NSCLC | PD-1 Inhibitor | Leptomeningeal Metastasis | Low Dose Radiotherapy

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage
University Ghent
Research Foundation Flanders

Recruiting

Exploring Prolonged AMR in ACL Reconstructed Patients

Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament Tear | Anterior Cruciate Ligament Reconstruction | ACL | ACL Injury | ACL Tear | Arthrogenic Muscle Inhibition | Arthrogenic Muscle Responses

Belgium

Search clinical trials for: Checkpoint Inhibition

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations